Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

Status unconfirmed · Not applicable

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying the side effects of doxorubicin hydrochloride liposome and to see how well it works in treating women with ductal carcinoma in situ undergoing surgery.

Key facts

Study ID

NCT00671476

Run by

Dr. Susan Love Research Foundation

People needed

30

Starts

2008-02-01

Last updated by the study team

2014-01-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• St. Joseph Hospital — Eureka, California, United States (enrolling)
• Doctor Susan Love Research Foundation — Santa Monica, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.